Cancer Generics Market Analysis
Across the globe, oncology market, one of the fastest growing segments of pharmaceutical industry, has been expanding on back of rising cancer incidences, and hefty investment by private players. According to our latest research report, the global cancer generics market is anticipated to grow at a compound annual rate of around 26% during 2011-2015 as many anti-cancer blockbuster drugs are on the verge of patent expiry, and governments are introducing biogenerics for controlling rapidly increasing healthcare costs.
The research report, “Cancer Generics Market Analysis”, finds that the future holds tremendous potential as many drugs are under the development stage, and upon commercialization, they will boost the market in a significant manner. Our comprehensive report has effectively provided an insight into the global cancer generics market through proper analysis of drivers, restraints and key developments. The thorough study asserts that the players in the market have demonstrated their capabilities in terms of new launches and effective marketing.
On studying the market trends and drivers, we found that the US hospitals have reported a generic chemotherapy drug shortage in the recent times. The sharp rise in the number of ANDA and DMFs, especially in the oncology segment, by players from emerging countries is one of the successful instances that compliment the current status of the cancer generics market. Our in-depth study evaluates the current status and future potential of generic drugs in disease indications, such as lung cancer, breast cancer, colon cancer, stomach cancer and prostate cancer.
Our report covers all the key aspects of the global cancer generics market, including the competitive landscape that discusses profiles of leading players like Hospira and Accord Healthcare. A brief overview of oral and injectable generics has also been provided in the extensive study that aims at presenting an impartial picture of the market to clients.
The research report, “Cancer Generics Market Analysis”, finds that the future holds tremendous potential as many drugs are under the development stage, and upon commercialization, they will boost the market in a significant manner. Our comprehensive report has effectively provided an insight into the global cancer generics market through proper analysis of drivers, restraints and key developments. The thorough study asserts that the players in the market have demonstrated their capabilities in terms of new launches and effective marketing.
On studying the market trends and drivers, we found that the US hospitals have reported a generic chemotherapy drug shortage in the recent times. The sharp rise in the number of ANDA and DMFs, especially in the oncology segment, by players from emerging countries is one of the successful instances that compliment the current status of the cancer generics market. Our in-depth study evaluates the current status and future potential of generic drugs in disease indications, such as lung cancer, breast cancer, colon cancer, stomach cancer and prostate cancer.
Our report covers all the key aspects of the global cancer generics market, including the competitive landscape that discusses profiles of leading players like Hospira and Accord Healthcare. A brief overview of oral and injectable generics has also been provided in the extensive study that aims at presenting an impartial picture of the market to clients.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. CANCER INCIDENCES - CURRENT AND FUTURE PROJECTION
4. CANCER MARKET OUTLOOK: CURRENT AND FUTURE
4.1 Cancer Generics: Market Size
5. MARKET DRIVERS AND TRENDS
5.1 US Facing Cancer Generics Shortage
5.2 Oncology Therapeutics: Major Focus Area
5.3 Strategic Activity and Alliances on the Rise
5.4 Companies Thriving for New Generic Cancer Drugs
6. CANCER GENERIC DRUGS: MARKET SEGMENTATION BY DISEASE TYPES
6.1 Lung Cancer
6.1.1 Current and Future Incidence
6.1.2 Regional Analysis
6.1.3 Commercialized Drugs: Branded and Generics
6.2 Breast Cancer
6.2.1 Current and Future Incidence
6.2.2 Regional Analysis
6.2.3 Commercialized Drugs: Branded and Generics
6.3 Colorectal Cancer
6.3.1 Current and Future Incidence
6.3.2 Regional Analysis
6.3.3 Commercialized Drugs: Branded and Generics
6.4 Stomach Cancer
6.4.1 Current and Future Incidence
6.4.2 Regional Analysis
6.4.3 Commercialized Drugs: Branded and Generics
6.5 Prostate Cancer
6.5.1 Current and Future Incidence
6.5.2 Regional Analysis
6.5.3 Commercialized Drugs: Branded and Generics
7. CANCER GENERIC DRUGS: MARKET SEGMENTATION BY ORAL AND INJECTABLES
7.1 Oral Generic Drugs
7.1.1 Arimidex (Anastrozole)
7.1.2 Casodex (Bicalutamide)
7.1.3 Aromasin (Exemestane)
7.1.4 Femara (Letrozole)
7.1.5 Megace (Megestrol Acetate)
7.1.6 Purinethol (Mercaptopurine)
7.1.7 Tarceva (Erlotinib)
7.1.8 Nolvadex (Tamoxifen Citrate)
7.1.9 Eulexin (Flutamide)
7.1.10 Hydrea (Hydroxyurea)
7.2 Generic Injectables
7.2.1 Camptosar (Irinotecan Hydrochloride)
7.2.2 Velcade (Bortezomib)
7.2.3 Taxotere (Docetaxel)
7.2.4 Gemzar (Gemcitabine Hydrochloride)
8. KEY PLAYERS
8.1 Accord Healthcare
8.2 Hospira
8.3 Mylan
8.4 Sun Pharmaceuticals
8.5 Teva
2. RESEARCH METHODOLOGY
3. CANCER INCIDENCES - CURRENT AND FUTURE PROJECTION
4. CANCER MARKET OUTLOOK: CURRENT AND FUTURE
4.1 Cancer Generics: Market Size
5. MARKET DRIVERS AND TRENDS
5.1 US Facing Cancer Generics Shortage
5.2 Oncology Therapeutics: Major Focus Area
5.3 Strategic Activity and Alliances on the Rise
5.4 Companies Thriving for New Generic Cancer Drugs
6. CANCER GENERIC DRUGS: MARKET SEGMENTATION BY DISEASE TYPES
6.1 Lung Cancer
6.1.1 Current and Future Incidence
6.1.2 Regional Analysis
6.1.3 Commercialized Drugs: Branded and Generics
6.2 Breast Cancer
6.2.1 Current and Future Incidence
6.2.2 Regional Analysis
6.2.3 Commercialized Drugs: Branded and Generics
6.3 Colorectal Cancer
6.3.1 Current and Future Incidence
6.3.2 Regional Analysis
6.3.3 Commercialized Drugs: Branded and Generics
6.4 Stomach Cancer
6.4.1 Current and Future Incidence
6.4.2 Regional Analysis
6.4.3 Commercialized Drugs: Branded and Generics
6.5 Prostate Cancer
6.5.1 Current and Future Incidence
6.5.2 Regional Analysis
6.5.3 Commercialized Drugs: Branded and Generics
7. CANCER GENERIC DRUGS: MARKET SEGMENTATION BY ORAL AND INJECTABLES
7.1 Oral Generic Drugs
7.1.1 Arimidex (Anastrozole)
7.1.2 Casodex (Bicalutamide)
7.1.3 Aromasin (Exemestane)
7.1.4 Femara (Letrozole)
7.1.5 Megace (Megestrol Acetate)
7.1.6 Purinethol (Mercaptopurine)
7.1.7 Tarceva (Erlotinib)
7.1.8 Nolvadex (Tamoxifen Citrate)
7.1.9 Eulexin (Flutamide)
7.1.10 Hydrea (Hydroxyurea)
7.2 Generic Injectables
7.2.1 Camptosar (Irinotecan Hydrochloride)
7.2.2 Velcade (Bortezomib)
7.2.3 Taxotere (Docetaxel)
7.2.4 Gemzar (Gemcitabine Hydrochloride)
8. KEY PLAYERS
8.1 Accord Healthcare
8.2 Hospira
8.3 Mylan
8.4 Sun Pharmaceuticals
8.5 Teva
LIST OF FIGURES:
Figure 3-1: Global - Number of New Cancer Cases (Million), 2009 & 2020
Figure 4-1: Global - Cancer Drugs Market (Billion US$), 2011-2015
Figure 4-2: Global - Cancer Market by Type of Drug (%), 2011
Figure 4-3: Global - Cancer Generics Market (Billion US$), 2011 & 2015
Figure 5-1: US - Share of Drug Type in Drugs Shortages
Figure 6-1: Global - Number of New Lung Cancer Cases (Million), 2009 & 2020
Figure 6-2: Global - New Lung Cancer Cases by Region (%), 2009
Figure 6-3: Global - Forecast for New Lung Cancer Cases by Region (%), 2020
Figure 6-4: Global - Number of New Breast Cancer Cases (Million), 2009 & 2020
Figure 6-5: Global - New Breast Cancer Cases by Region (%), 2009
Figure 6-6: Global - Forecast for New Breast Cancer Cases by Region (%), 2020
Figure 6-7: Global - Number of New Colorectal Cancer Cases (Million), 2009 & 2020
Figure 6-8: Global - New Colorectal Cancer Cases by Region (%), 2009
Figure 6-9: Global - Forecast for New Colorectal Cancer Cases by Region (%), 2020
Figure 6-10: Global - Number of New Stomach Cancer Cases (Million), 2009 & 2020
Figure 6-11: Global - New Stomach Cancer Cases by Region (%), 2009
Figure 6-12: Global - Forecast for New Stomach Cancer Cases by Region (%), 2020
Figure 6-13: Global - Number of New Prostate Cancer Cases (Million), 2009 & 2020
Figure 6-14: Global - New Prostate Cancer Cases by Region (%), 2009
Figure 6-15: Global - Forecast for New Prostate Cancer Cases by Region (%), 2020
Figure 3-1: Global - Number of New Cancer Cases (Million), 2009 & 2020
Figure 4-1: Global - Cancer Drugs Market (Billion US$), 2011-2015
Figure 4-2: Global - Cancer Market by Type of Drug (%), 2011
Figure 4-3: Global - Cancer Generics Market (Billion US$), 2011 & 2015
Figure 5-1: US - Share of Drug Type in Drugs Shortages
Figure 6-1: Global - Number of New Lung Cancer Cases (Million), 2009 & 2020
Figure 6-2: Global - New Lung Cancer Cases by Region (%), 2009
Figure 6-3: Global - Forecast for New Lung Cancer Cases by Region (%), 2020
Figure 6-4: Global - Number of New Breast Cancer Cases (Million), 2009 & 2020
Figure 6-5: Global - New Breast Cancer Cases by Region (%), 2009
Figure 6-6: Global - Forecast for New Breast Cancer Cases by Region (%), 2020
Figure 6-7: Global - Number of New Colorectal Cancer Cases (Million), 2009 & 2020
Figure 6-8: Global - New Colorectal Cancer Cases by Region (%), 2009
Figure 6-9: Global - Forecast for New Colorectal Cancer Cases by Region (%), 2020
Figure 6-10: Global - Number of New Stomach Cancer Cases (Million), 2009 & 2020
Figure 6-11: Global - New Stomach Cancer Cases by Region (%), 2009
Figure 6-12: Global - Forecast for New Stomach Cancer Cases by Region (%), 2020
Figure 6-13: Global - Number of New Prostate Cancer Cases (Million), 2009 & 2020
Figure 6-14: Global - New Prostate Cancer Cases by Region (%), 2009
Figure 6-15: Global - Forecast for New Prostate Cancer Cases by Region (%), 2020
LIST OF TABLES:
Table 3-1: Global - New Cases of Top Five Cancer’s by Geography (Number), 2009
Table 3-2: Global - Forecast for New Cases of Top Five Cancer’s by Geography (Number), 2020
Table 5-1: Oncology Drug Master Filings by Market Players
Table 6-1: Global - Key Lung Cancer Drugs and Patent Expiry Status
Table 6-2: Global - Key Breast Cancer Drugs and Patent Expiry Status
Table 6-3: Global - Key Colorectal Cancer Drugs and Patent Expiry Status
Table 6-4: Global - Key Stomach Cancer Drugs and Patent Expiry Status
Table 6-5: Global - Key Prostate Cancer Drugs and Patent Expiry Status
Table 7-1: List of Companies Dealing in Generic Arimidex (Anastrozole)
Table 7-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)
Table 7-3: List of Companies Dealing in Generic Casodex (Bicalutamide)
Table 7-4: Cost Comparison of Generics and Branded Casodex (Bicalutamide)
Table 7-5: Cost Comparison of Generics and Branded Aromasin (Exemestane)
Table 7-6: List of Companies Dealing in Generic Femara (Letrozole)
Table 7-7: Cost Comparison of Generics and Branded Femara (Letrozole)
Table 7-8: List of Companies Dealing in Generic Megace (Megestrol Acetate)
Table 7-9: Cost Comparison of Generics and Branded Megace (Megestrol Acetate)
Table 7-10: List of Companies Dealing in Generic Purinethol (Mercaptopurine)
Table 7-11 Cost Comparison of Generics and Branded Purinethol (Mercaptopurine)
Table 7-12 Cost Comparison of Generics and Branded Tarceva (Erlotinib)
Table 7-13: List of Companies Dealing in Generic Nolvadex (Tamoxifen Citrate)
Table 7-14 Cost Comparison of Generics and Branded Nolvadex (Tamoxifen Citrate)
Table 7-15: List of Companies Dealing in Generic Eulexin (Flutamide)
Table 7-16 Cost Comparison of Generics and Branded Eulexin (Flutamide)
Table 7-17: List of Companies Dealing in Generic Hydrea (Hydroxyurea)
Table 7-18 Cost Comparison of Generics and Branded Hydrea (Hydroxyurea)
Table 7-19: List of Companies Dealing in Generic Camptosar (Irinotecan Hydrochloride)
Table 7-20: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)
Table 7-21: Cost Comparison of Generics and Branded Velcade (bortezomib)
Table 7-22: List of Companies Dealing in Generic Taxotere (Docetaxel)
Table 7-23 Cost Comparison of Generics and Branded Taxotere (Docetaxel)
Table 7-24: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)
Table 7-25 Cost Comparison of Generics and Branded Gemzar (Gemcitabine Hydrochloride)
Table 8-1: Accord Healthcare - Key Cancer Generic Drugs
Table 8-2: Hospira - Key Cancer Generic Drugs
Table 8-3: Mylan - Key Cancer Generic Drugs
Table 8-4: Sun Pharmaceuticals - Key Cancer Generic Drugs
Table 8-5: Teva Pharmaceuticals - Key Cancer Generic Drugs
Table 3-1: Global - New Cases of Top Five Cancer’s by Geography (Number), 2009
Table 3-2: Global - Forecast for New Cases of Top Five Cancer’s by Geography (Number), 2020
Table 5-1: Oncology Drug Master Filings by Market Players
Table 6-1: Global - Key Lung Cancer Drugs and Patent Expiry Status
Table 6-2: Global - Key Breast Cancer Drugs and Patent Expiry Status
Table 6-3: Global - Key Colorectal Cancer Drugs and Patent Expiry Status
Table 6-4: Global - Key Stomach Cancer Drugs and Patent Expiry Status
Table 6-5: Global - Key Prostate Cancer Drugs and Patent Expiry Status
Table 7-1: List of Companies Dealing in Generic Arimidex (Anastrozole)
Table 7-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)
Table 7-3: List of Companies Dealing in Generic Casodex (Bicalutamide)
Table 7-4: Cost Comparison of Generics and Branded Casodex (Bicalutamide)
Table 7-5: Cost Comparison of Generics and Branded Aromasin (Exemestane)
Table 7-6: List of Companies Dealing in Generic Femara (Letrozole)
Table 7-7: Cost Comparison of Generics and Branded Femara (Letrozole)
Table 7-8: List of Companies Dealing in Generic Megace (Megestrol Acetate)
Table 7-9: Cost Comparison of Generics and Branded Megace (Megestrol Acetate)
Table 7-10: List of Companies Dealing in Generic Purinethol (Mercaptopurine)
Table 7-11 Cost Comparison of Generics and Branded Purinethol (Mercaptopurine)
Table 7-12 Cost Comparison of Generics and Branded Tarceva (Erlotinib)
Table 7-13: List of Companies Dealing in Generic Nolvadex (Tamoxifen Citrate)
Table 7-14 Cost Comparison of Generics and Branded Nolvadex (Tamoxifen Citrate)
Table 7-15: List of Companies Dealing in Generic Eulexin (Flutamide)
Table 7-16 Cost Comparison of Generics and Branded Eulexin (Flutamide)
Table 7-17: List of Companies Dealing in Generic Hydrea (Hydroxyurea)
Table 7-18 Cost Comparison of Generics and Branded Hydrea (Hydroxyurea)
Table 7-19: List of Companies Dealing in Generic Camptosar (Irinotecan Hydrochloride)
Table 7-20: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)
Table 7-21: Cost Comparison of Generics and Branded Velcade (bortezomib)
Table 7-22: List of Companies Dealing in Generic Taxotere (Docetaxel)
Table 7-23 Cost Comparison of Generics and Branded Taxotere (Docetaxel)
Table 7-24: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)
Table 7-25 Cost Comparison of Generics and Branded Gemzar (Gemcitabine Hydrochloride)
Table 8-1: Accord Healthcare - Key Cancer Generic Drugs
Table 8-2: Hospira - Key Cancer Generic Drugs
Table 8-3: Mylan - Key Cancer Generic Drugs
Table 8-4: Sun Pharmaceuticals - Key Cancer Generic Drugs
Table 8-5: Teva Pharmaceuticals - Key Cancer Generic Drugs
